Salvage Therapy with Vorinostat, Lenalidomide, and Dexamethasone (ZRD) in Lenalidomide/Dexamethasone Relapsed/Refractory Multiple Myeloma

被引：9
|
作者：
Richter, Joshua R. [1 ]
Bilotti, Elizabeth [1 ]
McBride, Laura [1 ]
Schmidt, Linda [1 ]
Gao, Zhijie [2 ]
Tufail, Madiha [2 ]
Anand, Palka [1 ]
McNeill, Ann [1 ]
Bednarz, Urszula [1 ]
Graef, Thorsten [3 ]
Vesole, David H. [1 ]
Siegel, David S. [1 ]
机构：
[1] Hackensack Univ, Med Ctr, John Theurer Canc Ctr, Hackensack, NJ USA
[2] Univ Med & Dent NJ, Newark, NJ USA
[3] Merck Res Labs, Upper Gwynedd, PA USA
来源：
BLOOD | 2011年 / 118卷 / 21期
关键词：
D O I：
10.1182/blood.V118.21.3986.3986
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1706 / 1706
页数：1
相关论文
共 50 条
  • [41] Lenalidomide plus dexamethasone treatment in Japanese patients with relapsed/refractory multiple myeloma
    Iida, Shinsuke
    Chou, Takaaki
    Okamoto, Shinichiro
    Nagai, Hirokazu
    Hatake, Kiyohiko
    Murakami, Hirokazu
    Takagi, Toshiyuki
    Shimizu, Kazuyuki
    Lau, Henry
    Takeshita, Kenichi
    Takatoku, Masaaki
    Hotta, Tomomitsu
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2010, 92 (01) : 118 - 126
  • [42] Efficacy of lenalidomide plus dexamethasone in relapsed/refractory multiple myeloma: A systematic review
    Tandy, Fenia
    Hadisurya, Audrey
    Suciningtias, Marlyn
    Chrystelle, Celine
    Kurniawan, Andree
    ANNALS OF ONCOLOGY, 2022, 33 : S489 - S489
  • [43] Expanded safety experience with lenalidomide plus dexamethasone in relapsed or refractory multiple myeloma
    Chen, Christine
    Reece, Donna E.
    Siegel, David
    Niesvizky, Ruben
    Boccia, Ralph V.
    Stadtmauer, Edward A.
    Abonour, Rafat
    Richardson, Paul
    Matous, Jeffrey
    Kumar, Shaji
    Bahlis, Nizar J.
    Alsina, Melissa
    Vescio, Robert
    Coutre, Steven E.
    Pietronigro, Dennis
    Knight, Robert D.
    Zeldis, Jerome B.
    Rajkumar, Vincent
    BRITISH JOURNAL OF HAEMATOLOGY, 2009, 146 (02) : 164 - 170
  • [44] Addition of daratumumab to the combination of lenalidomide and dexamethasone in relapsed or refractory myeloma
    Stocker, Nicolas
    HEMATOLOGIE, 2019, 25 (01): : 10 - 11
  • [45] Daratumumab, lenalidomide, and dexamethasone (DRd) vs lenalidomide and dexamethasone (Rd) in relapsed or refractory multiple myeloma (RRMM): Efficacy and safety update (POLLUX).
    Bahlis, Nizar J.
    Moreau, Philippe
    Nahi, Hareth
    Plesner, Torben
    Goldschmidt, Hartmut
    Suzuki, Kenshi
    Orlowski, Robert Z.
    Rabin, Neil
    Leiba, Merav
    Oriol, Albert
    Chari, Ajai
    Miguel, Jesus San
    Richardson, Paul G.
    Usmani, Saad Zafar
    O'Rourke, Lisa Marie
    Wu, Kaida
    Casneuf, Tineke
    Chiu, Christopher
    Qin, Xiang
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [46] Carfilzomib-Lenalidomide-Dexamethasone in the Management of Lenalidomide-Refractory Multiple Myeloma
    Cerchione, Claudio
    Catalano, Lucio
    Nappi, Davide
    Pareto, Anna Emanuele
    Musuraca, Gerardo
    Lucchesi, Alessandro
    Pane, Fabrizio
    Martinelli, Giovanni
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2020, 20 : S310 - S310
  • [47] Carfilzomib-Lenalidomide-Dexamethasone in the Management of Lenalidomide-Refractory Multiple Myeloma
    Cerchione, Claudio
    Martinelli, Giovanni
    Catalano, Lucio
    AMERICAN JOURNAL OF HEMATOLOGY, 2020, 95 : S5 - S6
  • [48] Carfilzomib-Lenalidomide-Dexamethasone in the Management of Lenalidomide-Refractory Multiple Myeloma
    Cerchione, Claudio
    Martinelli, Giovanni
    Nappi, Davide
    Pareto, Anna Emanuele
    Di Perna, Maria
    Ronconi, Sonia
    Pane, Fabrizio
    Catalano, Lucio
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 (10): : E358 - E359
  • [49] Vorinostat in combination with lenalidomide and dexamethasone in patients with relapsed or refractory multiple myeloma (vol 4, e182, 2014)
    Siegel, D. S.
    Richardson, P.
    Dimopoulos, M.
    Moreau, P.
    Mitsiades, C.
    Weber, D.
    Houp, J.
    Gause, C.
    Vuocolo, S.
    Eid, J.
    Graef, T.
    Anderson, K. C.
    BLOOD CANCER JOURNAL, 2014, 4 : e202 - e202
  • [50] Comparison of lenalidomide plus dexamethasone therapy used at first relapse versus later salvage therapy in relapsed or refractory multiple myeloma patients
    Stadtmauer, E. A.
    Weber, D. M.
    Nieszvizky, R.
    Belch, A.
    Prince, H. M.
    San Miguel, J. F.
    Facon, T.
    Yu, Z.
    Knight, R. D.
    Dimopoulos, M. A.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
12345